000163304 001__ 163304
000163304 005__ 20240322115504.0
000163304 0247_ $$2ISSN$$a1868-8497
000163304 0247_ $$2doi$$a10.1007/s12672-021-00422-9
000163304 0247_ $$2pmid$$apmid:35201440
000163304 0247_ $$2pmc$$apmc:PMC8777500
000163304 0247_ $$2altmetric$$aaltmetric:112724111
000163304 0247_ $$2ISSN$$a1868-8500
000163304 0247_ $$2ISSN$$a2730-6011
000163304 037__ $$aDZNE-2022-00084
000163304 041__ $$aEnglish
000163304 082__ $$a610
000163304 1001_ $$00000-0001-8094-2214$$aSun, Qiang$$b0
000163304 245__ $$aRecent advances in cancer immunotherapy.
000163304 260__ $$a[New York]$$bSpringer$$c2021
000163304 3367_ $$2DRIVER$$aarticle
000163304 3367_ $$2DataCite$$aOutput Types/Journal article
000163304 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711022460_32502$$xReview Article
000163304 3367_ $$2BibTeX$$aARTICLE
000163304 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163304 3367_ $$00$$2EndNote$$aJournal Article
000163304 500__ $$aJournal: Discover Oncology, ISSN: 2730-6011
000163304 520__ $$aCancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.
000163304 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000163304 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163304 650_7 $$2Other$$aCancer immunotherapy
000163304 650_7 $$2Other$$aCancer survival
000163304 650_7 $$2Other$$aImmune check point blockade
000163304 650_7 $$2Other$$aKRas
000163304 650_7 $$2Other$$aT cell receptor
000163304 650_7 $$2Other$$ap53
000163304 7001_ $$0P:(DE-2719)9001390$$aMelino, Gerry$$b1$$udzne
000163304 7001_ $$00000-0003-0739-325X$$aAmelio, Ivano$$b2
000163304 7001_ $$00000-0002-3128-9762$$aJiang, Jingting$$b3
000163304 7001_ $$00000-0002-2571-9367$$aWang, Ying$$b4
000163304 7001_ $$00000-0001-8964-319X$$aShi, Yufang$$b5
000163304 773__ $$0PERI:(DE-600)3059869-2$$a10.1007/s12672-021-00422-9$$gVol. 12, no. 1, p. 27$$n1$$p27$$tDiscover oncology$$v12$$x1868-8497$$y2021
000163304 8564_ $$uhttps://pub.dzne.de/record/163304/files/DZNE-2022-00084.pdf$$yOpenAccess
000163304 8564_ $$uhttps://pub.dzne.de/record/163304/files/DZNE-2022-00084.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163304 909CO $$ooai:pub.dzne.de:163304$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000163304 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001390$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000163304 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000163304 9141_ $$y2021
000163304 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000163304 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-29
000163304 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-29
000163304 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-29
000163304 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000163304 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-07-21T15:23:25Z
000163304 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-07-21T15:23:25Z
000163304 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000163304 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-29
000163304 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-29
000163304 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163304 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-07-21T15:23:25Z
000163304 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-29
000163304 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000163304 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000163304 9201_ $$0I:(DE-2719)5000018$$kAG Nicotera$$lSynaptic Connectivity and Neurodegeneration$$x0
000163304 980__ $$ajournal
000163304 980__ $$aVDB
000163304 980__ $$aUNRESTRICTED
000163304 980__ $$aI:(DE-2719)5000018
000163304 9801_ $$aFullTexts